Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Frank

Showing results (131-140 of 140) with videos related to

Pageof 14
Sort By:
You have reached the last page of results.This site can display upto 140 results.
Journal of the American College of Cardiology|January 17, 2015
Role of electrophysiological studies in predicting risk of ventricular arrhythmia in early repolarization syndromeSaagar Mahida, Nicolas Derval, Frederic Sacher, et al.
Journal of Medicinal Chemistry|September 11, 2012
2-(3-fluoro-4-methylsulfonylaminophenyl)propanamides as potent transient receptor potential vanilloid 1 (TRPV1) antagonists: structure-activity relationships of 2-amino derivatives in the N-(6-trifluoromethylpyridin-3-ylmethyl) C-regionMyeong Seop Kim, HyungChul Ryu, Dong Wook Kang, et al.
American Journal of Hematology|November 24, 2021
A phase 1 clinical trial of oral eltanexor in patients with relapsed or refractory multiple myelomaRobert Frank Cornell, Rachid Baz, Joshua R Richter, et al.
Nature|September 8, 2017
Stop this waste of people, animals and moneyDavid Moher, Larissa Shamseer, Kelly D Cobey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 31, 2018
Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple MyelomaDan T Vogl, David Dingli, Robert Frank Cornell, et al.
BMC Cancer|September 7, 2021
Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b studyGabriel Tremblay, Patrick Daniele, Janis Breeze, et al.
Nature Machine Intelligence|July 3, 2023
The immuneML ecosystem for machine learning analysis of adaptive immune receptor repertoiresMilena Pavlović, Lonneke Scheffer, Keshav Motwani, et al.
Leukemia|March 30, 2021
Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current eraBinod Dhakal, Sagar Patel, Saulius Girnius, et al.
Leukemia|June 6, 2021
Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current eraBinod Dhakal, Sagar Patel, Saulius Girnius, et al.
Leukemia|April 22, 2020
Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current eraBinod Dhakal, Sagar Patel, Saulius Girnius, et al.
Pageof 14

Showing results (131-140 of 140) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 140 results.
Journal of the American College of Cardiology|January 17, 2015
Role of electrophysiological studies in predicting risk of ventricular arrhythmia in early repolarization syndromeSaagar Mahida, Nicolas Derval, Frederic Sacher, et al.
Journal of Medicinal Chemistry|September 11, 2012
2-(3-fluoro-4-methylsulfonylaminophenyl)propanamides as potent transient receptor potential vanilloid 1 (TRPV1) antagonists: structure-activity relationships of 2-amino derivatives in the N-(6-trifluoromethylpyridin-3-ylmethyl) C-regionMyeong Seop Kim, HyungChul Ryu, Dong Wook Kang, et al.
American Journal of Hematology|November 24, 2021
A phase 1 clinical trial of oral eltanexor in patients with relapsed or refractory multiple myelomaRobert Frank Cornell, Rachid Baz, Joshua R Richter, et al.
Nature|September 8, 2017
Stop this waste of people, animals and moneyDavid Moher, Larissa Shamseer, Kelly D Cobey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 31, 2018
Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple MyelomaDan T Vogl, David Dingli, Robert Frank Cornell, et al.
BMC Cancer|September 7, 2021
Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b studyGabriel Tremblay, Patrick Daniele, Janis Breeze, et al.
Nature Machine Intelligence|July 3, 2023
The immuneML ecosystem for machine learning analysis of adaptive immune receptor repertoiresMilena Pavlović, Lonneke Scheffer, Keshav Motwani, et al.
Leukemia|March 30, 2021
Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current eraBinod Dhakal, Sagar Patel, Saulius Girnius, et al.
Leukemia|June 6, 2021
Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current eraBinod Dhakal, Sagar Patel, Saulius Girnius, et al.
Leukemia|April 22, 2020
Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current eraBinod Dhakal, Sagar Patel, Saulius Girnius, et al.
Pageof 14